Company Analysis Merrimack Pharmaceuticals, Inc.
1. Summary
Advantages
- Price (15.13 $) is less than fair price (16.23 $)
- The stock's return over the last year (0%) is higher than the sector average (-3.12%).
Disadvantages
- Dividends (0%) are below the sector average (0.55%).
- The company's current efficiency (ROE=-6.3%) is lower than the sector average (ROE=104.34%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Merrimack Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -14.2% | -2% |
| 90 days | 0% | -7.5% | 1.1% |
| 1 year | 0% | -3.1% | 16.1% |
MACK vs Sector: Merrimack Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 3.12% over the past year.
MACK vs Market: Merrimack Pharmaceuticals, Inc. has significantly underperformed the market by -16.08% over the past year.
Stable price: MACK is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MACK with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (15.13 $) is lower than the fair price (16.23 $).
Price not significantly lower than the fair price: The current price (15.13 $) is slightly lower than the fair price by 7.3%.
5.2. P/E
P/E vs Sector: The company's P/E (-183.2) is lower than that of the sector as a whole (35.84).
P/E vs Market: The company's P/E (-183.2) is lower than that of the market as a whole (-99.49).
5.3. P/BV
P/BV vs Sector: The company's P/BV (10.03) is lower than that of the sector as a whole (254.49).
P/BV vs Market: The company's P/BV (10.03) is lower than that of the market as a whole (71.88).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (-315.15) is lower than that of the sector as a whole (127.81).
P/S vs Market: The company's P/S indicator (-315.15) is lower than that of the market as a whole (113.77).
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-83.66) is lower than that of the sector as a whole (-27.35).
EV/Ebitda vs Market: The company's EV/Ebitda (-83.66) is lower than that of the market as a whole (-78.41).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -10.55% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-10.55%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-1802.65%).
6.4. ROE
ROE vs Sector: The company's ROE (-6.3%) is lower than that of the sector as a whole (104.34%).
ROE vs Market: The company's ROE (-6.3%) is lower than that of the market as a whole (-6.24%).
6.6. ROA
ROA vs Sector: The company's ROA (-6.15%) is lower than that of the sector as a whole (-2.2%).
ROA vs Market: The company's ROA (-6.15%) is lower than that of the market as a whole (38.46%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.59%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.55%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
